University of Hertfordshire

From the same journal

By the same authors

Optimisation of a dosing regime for a topical skin protectant (barrier cream)

Research output: Contribution to journalArticle

Standard

Optimisation of a dosing regime for a topical skin protectant (barrier cream). / Chilcott, Robert; Larner, Joanne; Matar, Hazem; Kansagra, Sneha; Theivendran, Baveetharan; Viegas, Vanessa Ann; Goldman, Virginia Streusand.

In: Cutaneous and Ocular Toxicology, Vol. 34, No. 4, 2015, p. 327-334.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{42942ce13602461ba63b03a8022fd386,
title = "Optimisation of a dosing regime for a topical skin protectant (barrier cream)",
abstract = "Context: Topical skin protectants (barrier creams) have the potential to reduce or enhance the severity of dermal lesions following exposure to allergens or irritants. Therefore, it is essential that such products are subject to appropriate clinical evaluation prior to marketing. Consequently, it is important to accurately define a dosing regime in order to assess test products under appropriate conditions. Objective: In this study, we extended the use of a standard rubefacient (methyl nicotinate; MN) assay to establish the optimum thickness and duration of action of a novel barrier cream (RD1433). White petroleum jelly (Vaseline{\circledR}) was used as a comparator product. Methods: The dermal response to MN was measured on the volar forearm skin of volunteers (n = 12; average age 47.5 years) using an array of biophysical instruments and visual scoring. When applied at a nominal thickness of 0.1 mm, RD1433 retained effectiveness against MN for up to six hours. In contrast, Vaseline{\circledR} was relatively ineffective. Moreover, RD1433 provoked no measurable signs of irritation and so can be considered acceptable for further clinical evaluation. Conclusion: Future clinical studies using RD1433 should be based on topical application of a 0.1 mm thickness layer every six hours.",
author = "Robert Chilcott and Joanne Larner and Hazem Matar and Sneha Kansagra and Baveetharan Theivendran and Viegas, {Vanessa Ann} and Goldman, {Virginia Streusand}",
year = "2015",
doi = "10.3109/15569527.2014.994124",
language = "English",
volume = "34",
pages = "327--334",
journal = "Cutaneous and Ocular Toxicology",
issn = "1556-9527",
publisher = "Informa Healthcare",
number = "4",

}

RIS

TY - JOUR

T1 - Optimisation of a dosing regime for a topical skin protectant (barrier cream)

AU - Chilcott, Robert

AU - Larner, Joanne

AU - Matar, Hazem

AU - Kansagra, Sneha

AU - Theivendran, Baveetharan

AU - Viegas, Vanessa Ann

AU - Goldman, Virginia Streusand

PY - 2015

Y1 - 2015

N2 - Context: Topical skin protectants (barrier creams) have the potential to reduce or enhance the severity of dermal lesions following exposure to allergens or irritants. Therefore, it is essential that such products are subject to appropriate clinical evaluation prior to marketing. Consequently, it is important to accurately define a dosing regime in order to assess test products under appropriate conditions. Objective: In this study, we extended the use of a standard rubefacient (methyl nicotinate; MN) assay to establish the optimum thickness and duration of action of a novel barrier cream (RD1433). White petroleum jelly (Vaseline®) was used as a comparator product. Methods: The dermal response to MN was measured on the volar forearm skin of volunteers (n = 12; average age 47.5 years) using an array of biophysical instruments and visual scoring. When applied at a nominal thickness of 0.1 mm, RD1433 retained effectiveness against MN for up to six hours. In contrast, Vaseline® was relatively ineffective. Moreover, RD1433 provoked no measurable signs of irritation and so can be considered acceptable for further clinical evaluation. Conclusion: Future clinical studies using RD1433 should be based on topical application of a 0.1 mm thickness layer every six hours.

AB - Context: Topical skin protectants (barrier creams) have the potential to reduce or enhance the severity of dermal lesions following exposure to allergens or irritants. Therefore, it is essential that such products are subject to appropriate clinical evaluation prior to marketing. Consequently, it is important to accurately define a dosing regime in order to assess test products under appropriate conditions. Objective: In this study, we extended the use of a standard rubefacient (methyl nicotinate; MN) assay to establish the optimum thickness and duration of action of a novel barrier cream (RD1433). White petroleum jelly (Vaseline®) was used as a comparator product. Methods: The dermal response to MN was measured on the volar forearm skin of volunteers (n = 12; average age 47.5 years) using an array of biophysical instruments and visual scoring. When applied at a nominal thickness of 0.1 mm, RD1433 retained effectiveness against MN for up to six hours. In contrast, Vaseline® was relatively ineffective. Moreover, RD1433 provoked no measurable signs of irritation and so can be considered acceptable for further clinical evaluation. Conclusion: Future clinical studies using RD1433 should be based on topical application of a 0.1 mm thickness layer every six hours.

U2 - 10.3109/15569527.2014.994124

DO - 10.3109/15569527.2014.994124

M3 - Article

C2 - 25597377

VL - 34

SP - 327

EP - 334

JO - Cutaneous and Ocular Toxicology

JF - Cutaneous and Ocular Toxicology

SN - 1556-9527

IS - 4

ER -